Holen Sie sich die Stockscreener-App
1.81
4.23%
-0.08
Handel nachbörslich:
1.82
0.01
+0.55%
Schlusskurs vom Vortag:
$1.89
Offen:
$1.88
24-Stunden-Volumen:
1.99M
Relative Volume:
0.38
Marktkapitalisierung:
$67.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-57.91M
KGV:
-1.2937
EPS:
-1.3991
Netto-Cashflow:
$-38.14M
1W Leistung:
-4.74%
1M Leistung:
-21.98%
6M Leistung:
-87.07%
1J Leistung:
-73.42%
1-Tages-Spanne:
$1.81
$1.93
1-Wochen-Bereich:
$1.80
$1.95
52-Wochen-Spanne:
$1.31
$19.40
Tenax Therapeutics Inc Stock (TENX) Company Profile
Firmenname
Tenax Therapeutics Inc
Sektor
Branche
Telefon
919-855-2100
Adresse
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
1.81 | 67.74M | 0 | -57.91M | -38.14M | -1.3991 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-08 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-24 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-14 | Eingeleitet | Guggenheim | Buy |
| 2024-09-30 | Eingeleitet | William Blair | Outperform |
| 2017-05-18 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | Eingeleitet | MLV & Co | Buy |
| 2014-11-18 | Eingeleitet | WallachBeth | Buy |
Alle ansehen
Tenax Therapeutics Inc Aktie (TENX) Neueste Nachrichten
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know - Eastern Progress
Independent Director of Tenax Therapeutics Declan Doogan Buys 2,331% More Shares - webull.com
Tenax Therapeutics, Inc.(NasdaqCM: TENX) added to S&P Global BMI Index - marketscreener.com
Tenax Therapeutics Inc (NASDAQ: TENX) Share Price, TENX Stock News, TENX Share Price & Updates - kalkine.com.au
Tenax Therapeutics director Declan Doogan buys $101,760 in shares - Investing.com India
Director Declan Doogan Buys 53,000 Shares of Tenax Therapeutics Inc (TENX) - GuruFocus
Tenax Therapeutics director Declan Doogan buys $101,760 in shares By Investing.com - Investing.com Canada
ING Groep NV Exits Tenax Therapeutics Inc (TENX) Position in Ful - GuruFocus
Piper Sandler Remains a Buy on Tenax Therapeutics (TENX) - The Globe and Mail
Tenax Therapeutics CEO Christopher Giordano acquires $20,087 in shares By Investing.com - Investing.com South Africa
Tenax Therapeutics (TENX) CEO Christopher Giordano Buys 10,850 S - GuruFocus
Tenax Therapeutics CFO buys $10,981 in common stock - Investing.com
Tenax Therapeutics CFO buys $10,981 in common stock By Investing.com - Investing.com Canada
TENAX Therapeutics (NASDAQ: TENX) Reports Zero ING Groep N.V. and ING Capital Markets LLC Ownership on 37,423,917 Shares - Kalkine Media
ING Groep reports zero stake in Tenax Therapeutics (TENX) - Stock Titan
Tenax Therapeutics Stock Short Interest Rises to 35.39% - Quiver Quantitative
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Tenax Therapeutics stock rating at overweight - Investing.com
Tenax at Cantor conference: trial miss sharpens next-step strategy By Investing.com - Investing.com India
Tenax Therapeutics Updates Phase 3 LEVEL Trial Strategy - tipranks.com
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics - Investing.com Australia
Adar1 Capital Management, 10% owner, buys $1.6m in Tenax Therapeutics By Investing.com - Investing.com South Africa
ADAR1 Capital Management, LLC Expands Tenax Therapeutics Inc (TE - GuruFocus
ADAR1 funds boost Tenax Therapeutics (TENX) stake in latest buy - Stock Titan
One manager just reported a 14% holding in Tenax Therapeutics (TENX) - Stock Titan
FMR LLC reports 514,925-share stake in Tenax (NASDAQ: TENX) - Stock Titan
TENX Form 4 FilingsTenax Therapeutics, Inc. SEC Form 4 - Stock Titan
TENX Jumps As Tenax Therapeutics Pivots Phase 3 Strategy - timothysykes.com
Tenax Therapeutics Stock Wobbles After Mixed Phase 3 Data - timothysykes.com
Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable? - Yahoo Finance
Sphera Funds Management Boosts Tenax Therapeutics Stake in High-Risk Biotech Bet - GuruFocus
Investment funds tied to Tenax (TENX) 10% owner just bought more stock - Stock Titan
CCORF Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Stock Titan
TENX Downgraded by Guggenheim -- Rating Updated to Neutral - GuruFocus
Piper Sandler Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Guggenheim Downgrades TENX to Neutral Amid Uncertain Clinical Ou - GuruFocus
Why is Tenax Therapeutics stock volatile today? By Investing.com - Investing.com Canada
Tenax Therapeutics (TENX) Phase 3 Data Spurs Focus on Subgroup B - GuruFocus
Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss (TENX:NASDAQ) - Seeking Alpha
Tenax presents additional Phase 3 trial data for TNX-103 By Investing.com - Investing.com Nigeria
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 - Investing News Network
ING Groep reveals passive stake in Tenax Therapeutics (ING) - Stock Titan
New 5.3% backer emerges in Tenax Therapeutics (NASDAQ: TENX) - Stock Titan
Tenax Therapeutics Stock (TENX) Opinions on Recent Insider Purchases and Gains - quiverquant.com
Tenax rises on over $1.8M insider buying (TENX:NASDAQ) - Seeking Alpha
Finanzdaten der Tenax Therapeutics Inc-Aktie (TENX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):